Gilead Sciences Inc (GILD) Financial Statements
Historical financial data — 41 statements covering FY2016–FY2025
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition o...
Gilead Sciences Inc's revenue increased 2.4% year over year, from $28.75B to $29.44B.
Net income increased 1672.9% over the same period, from $480.0M to $8.51B.
Over the 9-year period from FY2016 to FY2025, revenue declined by 3% in total.
Total debt decreased by 6.6% to $24.94B.
The debt-to-equity ratio stands at 1.10, indicating a elevated leverage profile.
Operating cash flow declined 7.5% to $10.02B.
Gilead Sciences Inc maintains a strong net profit margin of 28.9%.
Recent Financial Statements
| Period | Revenue | Net Income | Gross Profit | EBIT | Op. Cash Flow | Total Assets | Total Debt | Equity |
|---|---|---|---|---|---|---|---|---|
| Q3 FY2023 | $20.00B+54.4% | $4.24B | $15.59B | $5.99B | $5.84B | $62.37B | $24.98B | $22.31B |
| Q1 FY2024 | $6.69B-66.6% | $-4.17B | $5.13B | $-4.32B | $2.22B | $56.29B | $25.19B | $17.54B |
| Q2 FY2024 | $13.64B+104.0% | $-2.56B | $10.54B | $-1.68B | $3.54B | $53.58B | $23.35B | $18.28B |
| Q3 FY2024 | $21.18B+55.3% | $-1.30B | $16.52B | $-790.0M | $7.85B | $54.52B | $23.25B | $18.48B |
| Q1 FY2025 | $6.67B-68.5% | $1.31B | $5.13B | $2.24B | $1.76B | $56.43B | $24.95B | $19.16B |
| Q2 FY2025 | $13.75B+106.2% | $3.27B | $10.71B | $4.71B | $2.58B | $55.72B | $24.95B | $19.67B |
| Q3 FY2025 | $21.52B+56.5% | $6.33B | $16.91B | $8.04B | $6.69B | $58.53B | $24.94B | $21.54B |
| Q1 FY2026 | $6.96B-67.7% | $2.02B | $5.51B | $2.59B | $2.54B | $56.28B | $22.17B | $23.52B |
Balance Sheet Summary (Latest Period)
Total Assets
$59.02B
Total Liabilities
$36.32B
Total Equity
$22.70B
Cash & Equivalents
$68.0M
Total Debt
$24.94B
Current Assets
$18.34B
Current Liabilities
$11.81B
Retained Earnings
$13.73B